Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Yasue TakeuchiNorio AkutaHitomi SezakiFumitaka SuzukiShunichirou FujiyamaYusuke KawamuraTetsuya HosakaMasahiro KobayashiMariko KobayashiSatoshi SaitohYoshiyuki SuzukiYasuji AraseKenji IkedaHiromitsu KumadaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)
Treatment with EBR/GZR was highly efficacious with acceptable safety, even in patients with CKD stage 4-5. Retreatment of relapsers to prior DAAs, excluding ledipasvir and sofosbuvir, achieved SVR12.